NDAORALTABLET
Approved
Jan 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
URISPAS (flavoxate hydrochloride) by Johnson & Johnson is clinical pharmacology flavoxate hydrochloride counteracts smooth muscle spasm of the urinary tract and exerts its effect directly on the muscle. First approved in 1970.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
URISPAS (flavoxate hydrochloride) is an oral antispasmodic small molecule approved in 1970 that directly counteracts smooth muscle spasm of the urinary tract. It is indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, and urinary incontinence associated with urological conditions. The drug achieves peak effect within ~112 minutes and is rapidly excreted via urine.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on cost containment and managed transition rather than aggressive growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Flavoxate hydrochloride counteracts smooth muscle spasm of the urinary tract and exerts its effect directly on the muscle. In a single study of 11 normal male subjects, the time to onset of action was 55 minutes. The peak effect was observed at 112 minutes. 57% of the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on URISPAS offers limited career advancement due to its LOE-approaching status and mature market position; roles are primarily focused on defending market share and managing transition to generic competition. This assignment is better suited for professionals seeking to learn legacy product management or cost-containment strategies rather than high-growth innovation roles.
Brand Manager
Worked on URISPAS at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.